Histone deacetylase 10

Description:

Description
  • Accession: Q969S8
  • Swissprot: HDA10_HUMAN
  • Organism: Homo sapiens
  • Gene: HDAC10
  • Target class: Enzyme

Drug Relations:

belinostat
a hydroxamate-type inhibitor of histone deacetylase Bioactivity details MOA
chidamide
An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Chidamide binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life. Bioactivity details MOA
panobinostat
An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA. Bioactivity details MOA
romidepsin
a bicyclic depsipeptide and a potent histone deacetylase inhibitor from Chromobacterium violaceum Bioactivity details MOA
bendamustine
A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA. Bioactivity details MOA
bufexamac
A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally. Bioactivity details MOA
vorinostat
A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. Bioactivity details MOA